Image talk:Nimodipine.png

From Wikipedia, the free encyclopedia

Indications /Uses : Nimotop 30mg soft gelatin capsules manufactured by Bayer (Nimodipine) is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured congenital aneurysms who are in good neurological condition post- ictus (e.g., Hunt and Hess Grades I-III).

NIMOTOP 30mg capsules are formulated as soft gelatin capsules for oral administration by Bayer Corporation.

Pharmacokinetics: Rapidly absorbed orally with Tmax of 1hr. Rapidly eliminated requiring every 4hr dosing. BA only 13% due to extensive first pass effect. A study comparing the tablet form of nimodipine with the softgel indicated two fold higher Cmax and slightly higher (9-38%) AUC with the softgel (Ref.SBA). The study concluded that the Nimodipine is more bioavailable from softgel than from tablet. Dosage and administration: Nimotop is given orally in the form of ivory colored soft gelatin 30 mg capsules for subarachnoid hemorrhage.

The oral dose is 60 mg (two 30 mg capsules) every 4 hours for 21 consecutive days, preferably not less than one hour before or two hours after meals. If the capsule cannot be swallowed, e.g., at the time of surgery or if the patient is unconscious, a hole should be made in both ends of the capsule with an 18 gauge needle, and the contents of the capsule extracted into a syringe. The contents should then be emptied into the patient's in situ naso-gastric tube and washed down the tube with 30 mL of normal saline (0.9%).

The contents of Nimotop capsules must not be administered by intravenous injection or other parenteral routes.